{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:13:53Z","timestamp":1767978833169,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals, Inc.","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals Ltd","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Understanding patients\u2019 perspectives regarding drug tolerability, in addition to effectiveness, provides a complete picture of the patient experience and supports more informed therapeutic decision-making. The item library of the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed to measure patient-reported frequency, severity, and interference of adverse events (AEs) associated with cancer therapies. This qualitative interview study assessed the suitability of items selected from the PRO-CTCAE library for assessing tolerability of selexipag, a medication targeting the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two rounds of 10 qualitative, web-assisted telephone interviews following a semi-structured guide were conducted in individuals with recent experience taking oral selexipag for PAH. Each interview included concept elicitation to gather participants\u2019 perspectives on symptomatic AEs (type, frequency, severity, and interference) and cognitive debriefing of PRO-CTCAE items addressing the most frequently reported AEs of oral selexipag.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Interviews were conducted with 20 participants with PAH (mean [range] age 50 [24\u201368] years; 75% female; 85% in World Health Organization Functional Class II\u2013III), comprising different races\/ethnicities, levels of education, and employment status. Fifteen participants were currently treated with selexipag; five had taken selexipag for \u2265\u20096 months before discontinuing. The most frequently reported AEs included headache, jaw pain, and nausea (n\u2009=\u200915, 12, and 10 participants, respectively). Diarrhea and headache were identified as the most bothersome AEs by 5 and 4 participants, respectively. Some AEs were transitory (e.g., jaw pain); others were long-lasting (e.g., muscle pain). Based on findings from Round 1 interviews, a flushing item was added and the PRO-CTCAE general pain item was modified to be specific to jaw pain for testing in Round 2. Interview findings identified the following AEs as relevant to assess in a PAH clinical trial: nausea, vomiting, diarrhea, flushing, jaw pain, headache, aching muscles, and aching joints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The PRO-CTCAE items selected in this study and the additional symptomatic AEs identified as patient-relevant have the potential to be included in assessments capturing the patient perspective on tolerability in future studies of selexipag and possibly other PAH therapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00673-w","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T07:02:12Z","timestamp":1702882932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag"],"prefix":"10.1186","volume":"7","author":[{"given":"Stacy","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Norcross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri","family":"Fehnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Beaudet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Fastenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"6","key":"673_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","volume":"21","author":"PG Kluetz","year":"2018","unstructured":"Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K et al (2018) Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute workshop. Value Health 21(6):742\u2013747. https:\/\/doi.org\/10.1016\/j.jval.2017.09.009","journal-title":"Value Health"},{"issue":"2","key":"673_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bcp.15016","volume":"88","author":"V Stanulovic","year":"2022","unstructured":"Stanulovic V, Hodolic M, Mitsikostas DD, Papadopoulos D (2022) Drug tolerability: how much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. Br J Clin Pharmacol 88(2):551\u2013565. https:\/\/doi.org\/10.1111\/bcp.15016","journal-title":"Br J Clin Pharmacol"},{"key":"673_CR3","unstructured":"Basch E, Campbell A, Hudgens S, Jones L, King-Kallimanis B, Kluetz P et al (2018) Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience: a Friends of Cancer Research White Paper. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Comparative-Tolerability-Whitepaper_FINAL.pdf. Accessed 24 July 2023"},{"key":"673_CR4","doi-asserted-by":"publisher","unstructured":"Chalasani M, Vaidya P, Mullin T (2018) Enhancing the incorporation of the patient\u2019s voice in drug development and evaluation. Res Involv Engagem 4(10). https:\/\/doi.org\/10.1186\/s40900-018-0093-3","DOI":"10.1186\/s40900-018-0093-3"},{"issue":"5","key":"673_CR5","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","volume":"19","author":"PG Kluetz","year":"2018","unstructured":"Kluetz PG, O\u2019Connor DJ, Soltys K (2018) Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol 19(5):e267\u2013e274. https:\/\/doi.org\/10.1016\/S1470-2045(18)30097-4","journal-title":"Lancet Oncol"},{"key":"673_CR6","doi-asserted-by":"publisher","unstructured":"Kuehn CM (2019) A proposed framework for patient-focused policy at the U.S. Food and Drug Administration. Biomedicines 7(3). https:\/\/doi.org\/10.3390\/biomedicines7030064","DOI":"10.3390\/biomedicines7030064"},{"issue":"1","key":"673_CR7","doi-asserted-by":"publisher","first-page":"1542920","DOI":"10.1080\/20016689.2018.1542920","volume":"6","author":"S Jaroslawski","year":"2018","unstructured":"Jaroslawski S, Auquier P, Borissov B, Dussart C, Toumi M (2018) Patient-reported outcome claims in European and United States orphan drug approvals. J Mark Access Health Policy 6(1):1542920. https:\/\/doi.org\/10.1080\/20016689.2018.1542920","journal-title":"J Mark Access Health Policy"},{"issue":"2","key":"673_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","volume":"22","author":"A Gnanasakthy","year":"2019","unstructured":"Gnanasakthy A, Barrett A, Evans E, D\u2019Alessio D, Romano CD (2019) A review of patient-reported outcomes labeling for oncology Drugs approved by the FDA and the EMA (2012\u20132016). Value Health 22(2):203\u2013209. https:\/\/doi.org\/10.1016\/j.jval.2018.09.2842","journal-title":"Value Health"},{"issue":"1","key":"673_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s13142-011-0025-3","volume":"1","author":"DW Bruner","year":"2011","unstructured":"Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L et al (2011) Stakeholder perspectives on implementing the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Transl Behav Med 1(1):110\u2013122. https:\/\/doi.org\/10.1007\/s13142-011-0025-3","journal-title":"Transl Behav Med"},{"issue":"9","key":"673_CR10","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9):dju244. https:\/\/doi.org\/10.1093\/jnci\/dju244","journal-title":"J Natl Cancer Inst"},{"key":"673_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","volume":"35","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Chingos DT, Basch EM, Mitchell SA (2016) Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 35:67\u201373. https:\/\/doi.org\/10.1200\/EDBK_159514","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"673_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P et al (2021) Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials 18(1):104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120","journal-title":"Clin Trials"},{"key":"673_CR13","unstructured":"National Cancer Institute (2022) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u00ae). https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/. Accessed 24 July 2023"},{"issue":"1","key":"673_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11136-013-0470-1","volume":"23","author":"JL Hay","year":"2014","unstructured":"Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G et al (2014) Cognitive interviewing of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257\u2013269. https:\/\/doi.org\/10.1007\/s11136-013-0470-1","journal-title":"Qual Life Res"},{"issue":"8","key":"673_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ et al (2015) Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051\u20131059. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639","journal-title":"JAMA Oncol"},{"issue":"4","key":"673_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jpainsymman.2016.11.006","volume":"53","author":"BB Reeve","year":"2017","unstructured":"Reeve BB, McFatrich M, Pinheiro LC, Freyer DR, Basch EM, Baker JN et al (2017) Cognitive interview-based validation of the patient-reported outcomes version of the common terminology criteria for adverse events in adolescents with cancer. J Pain Symptom Manage 53(4):759\u2013766. https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.11.006","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"673_CR17","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jpainsymman.2017.10.024","volume":"55","author":"TM Atkinson","year":"2018","unstructured":"Atkinson TM, Hay JL, Dueck AC, Mitchell SA, Mendoza TR, Rogak LJ et al (2018) What do none, mild, moderate, severe, and very severe mean to patients with cancer? Content validity of PRO-CTCAE response scales. J Pain Symptom Manage 55(3):e3\u2013e6. https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.10.024","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"673_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41591-021-01648-4","volume":"28","author":"A Retzer","year":"2022","unstructured":"Retzer A, Aiyegbusi OL, Rowe A, Newsome PN, Douglas-Pugh J, Khan S et al (2022) The value of patient-reported outcomes in early-phase clinical trials. Nat Med 28(1):18\u201320. https:\/\/doi.org\/10.1038\/s41591-021-01648-4","journal-title":"Nat Med"},{"issue":"9","key":"673_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3899\/jrheum.210688","volume":"49","author":"GS Hazlewood","year":"2022","unstructured":"Hazlewood GS, Schieir O, Bykerk V, Mujaab K, Tugwell P, Wells G et al (2022) Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey. J Rheumatol 49(9):998\u20131005. https:\/\/doi.org\/10.3899\/jrheum.210688","journal-title":"J Rheumatol"},{"issue":"9","key":"673_CR20","doi-asserted-by":"publisher","first-page":"e063199","DOI":"10.1136\/bmjopen-2022-063199","volume":"12","author":"SE Hughes","year":"2022","unstructured":"Hughes SE, McMullan C, Rowe A, Retzer A, Malpass R, Bathurst C et al (2022) Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory Disease (PROmics): protocol for a qualitative feasibility study. BMJ Open 12(9):e063199. https:\/\/doi.org\/10.1136\/bmjopen-2022-063199","journal-title":"BMJ Open"},{"issue":"2","key":"673_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jval.2015.11.002","volume":"19","author":"BM Craig","year":"2016","unstructured":"Craig BM, Mitchell SA (2016) Examining the value of menopausal symptom relief among US women. Value Health 19(2):158\u2013166. https:\/\/doi.org\/10.1016\/j.jval.2015.11.002","journal-title":"Value Health"},{"issue":"1","key":"673_CR22","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al (2023) 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61(1):2200879. https:\/\/doi.org\/10.1183\/13993003.00879-2022","journal-title":"Eur Respir J"},{"issue":"25","key":"673_CR23","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun PM (2021) Pulmonary arterial hypertension. N Engl J Med 385(25):2361\u20132376. https:\/\/doi.org\/10.1056\/NEJMra2000348","journal-title":"N Engl J Med"},{"issue":"1","key":"673_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jpainsymman.2015.07.012","volume":"51","author":"LA Matura","year":"2016","unstructured":"Matura LA, McDonough A, Carroll DL (2016) Symptom interference severity and health-related quality of life in pulmonary arterial hypertension. J Pain Symptom Manage 51(1):25\u201332. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.07.012","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"673_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","volume":"18","author":"M Burks","year":"2018","unstructured":"Burks M, Stickel S, Gali\u00e8 N (2018) Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs 18(4):249\u2013257. https:\/\/doi.org\/10.1007\/s40256-018-0272-5","journal-title":"Am J Cardiovasc Drugs"},{"issue":"142","key":"673_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1183\/16000617.0083-2016","volume":"25","author":"HW Farber","year":"2016","unstructured":"Farber HW, Gin-Sing W (2016) Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev 25(142):418\u2013430. https:\/\/doi.org\/10.1183\/16000617.0083-2016","journal-title":"Eur Respir Rev"},{"key":"673_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.rmed.2018.09.002","volume":"143","author":"S Lombardi","year":"2018","unstructured":"Lombardi S, Kingman M, Duncan M, Berngard SC, Fernandes T (2018) Titration of pulmonary arterial hypertension therapeutics: experience-based recommendations. Respir Med 143:139\u2013146. https:\/\/doi.org\/10.1016\/j.rmed.2018.09.002","journal-title":"Respir Med"},{"issue":"26","key":"673_CR28","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522\u20132533. https:\/\/doi.org\/10.1056\/NEJMoa1503184","journal-title":"N Engl J Med"},{"key":"673_CR29","unstructured":"Actelion Pharmaceuticals US Inc (2022) Uptravi\u00ae (selexipag) Product Information. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/UPTRAVI-pi.pdf. Accessed 24 July 2023"},{"key":"673_CR30","unstructured":"Janssen-Cilag International NV (2022) Uptravi\u00ae (selexipag) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/uptravi-epar-product-information_en.pdf. Accessed 24 July 2023"},{"issue":"10","key":"673_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP et al (2010) What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health 25(10):1229\u20131245. https:\/\/doi.org\/10.1080\/08870440903194015","journal-title":"Psychol Health"},{"issue":"1","key":"673_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12874-018-0594-7","volume":"18","author":"K Vasileiou","year":"2018","unstructured":"Vasileiou K, Barnett J, Thorpe S, Young T (2018) Characterising and justifying sample size sufficiency in interview-based studies: systematic analysis of qualitative health research over a 15-year period. BMC Med Res Methodol 18(1):148. https:\/\/doi.org\/10.1186\/s12874-018-0594-7","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"673_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014","journal-title":"Value Health"},{"issue":"1","key":"673_CR34","doi-asserted-by":"publisher","first-page":"1801904","DOI":"10.1183\/13993003.01904-2018","volume":"53","author":"A Frost","year":"2019","unstructured":"Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A et al (2019) Diagnosis of pulmonary hypertension. Eur Respir J 53(1):1801904. https:\/\/doi.org\/10.1183\/13993003.01904-2018","journal-title":"Eur Respir J"},{"key":"673_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2023.09.016","author":"V McLaughlin","year":"2023","unstructured":"McLaughlin V, Farber HW, Highland KB, Hemnes AR, Chakinala MM, Chin KM et al (2023) Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). J Heart Lung Transplant. https:\/\/doi.org\/10.1016\/j.healun.2023.09.016","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"673_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12955-021-01782-0","volume":"19","author":"KB Highland","year":"2021","unstructured":"Highland KB, Crawford R, Classi P, Morrison R, Doward L, Nelsen AC et al (2021) Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure. Health Qual Life Outcomes 19(1):202. https:\/\/doi.org\/10.1186\/s12955-021-01782-0","journal-title":"Health Qual Life Outcomes"},{"issue":"1 Suppl","key":"673_CR37","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1378\/chest.126.1_suppl.7S","volume":"126","author":"LJ Rubin","year":"2004","unstructured":"Rubin LJ (2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):7S\u201310S. https:\/\/doi.org\/10.1378\/chest.126.1_suppl.7S","journal-title":"Chest"},{"issue":"2","key":"673_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa","journal-title":"Qual Res Psychol"},{"issue":"4","key":"673_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00432-016-2335-9","volume":"143","author":"TM Atkinson","year":"2017","unstructured":"Atkinson TM, Rogak LJ, Heon N, Ryan SJ, Shaw M, Stark LP et al (2017) Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol 143(4):735\u2013743. https:\/\/doi.org\/10.1007\/s00432-016-2335-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"673_CR40","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/2045893217719250","volume":"7","author":"M Kingman","year":"2017","unstructured":"Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, Lombardi S (2017) Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ 7(3):598\u2013608. https:\/\/doi.org\/10.1177\/2045893217719250","journal-title":"Pulm Circ"},{"issue":"1 Suppl","key":"673_CR41","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","volume":"54","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Gali\u00e8 N et al (2009) End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S97\u2013107. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"673_CR42","doi-asserted-by":"publisher","first-page":"1801908","DOI":"10.1183\/13993003.01908-2018","volume":"53","author":"O Sitbon","year":"2019","unstructured":"Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M et al (2019) Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J 53(1):1801908. https:\/\/doi.org\/10.1183\/13993003.01908-2018","journal-title":"Eur Respir J"},{"key":"673_CR43","unstructured":"US Food and Drug Administration (2009) Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 24 July 2023"},{"issue":"1","key":"673_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.chest.2020.07.088","volume":"159","author":"JB Badlam","year":"2021","unstructured":"Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW et al (2021) United States Pulmonary Hypertension Scientific Registry: baseline characteristics. Chest 159(1):311\u2013327. https:\/\/doi.org\/10.1016\/j.chest.2020.07.088","journal-title":"Chest"},{"issue":"3","key":"673_CR45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","volume":"155","author":"JR Klinger","year":"2019","unstructured":"Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K et al (2019) Therapy for pulmonary arterial hypertension in adults: update of the CHEST Guideline and Expert Panel Report. Chest 155(3):565\u2013586. https:\/\/doi.org\/10.1016\/j.chest.2018.11.030","journal-title":"Chest"},{"issue":"4","key":"673_CR46","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.chest.2019.10.043","volume":"157","author":"VV McLaughlin","year":"2020","unstructured":"McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galie N et al (2020) Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents. Chest 157(4):955\u2013965. https:\/\/doi.org\/10.1016\/j.chest.2019.10.043","journal-title":"Chest"},{"issue":"4","key":"673_CR47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903\u2013975. https:\/\/doi.org\/10.1183\/13993003.01032-2015","journal-title":"Eur Respir J"},{"issue":"1","key":"673_CR48","doi-asserted-by":"publisher","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","volume":"53","author":"N Gali\u00e8","year":"2019","unstructured":"Gali\u00e8 N, Channick RN, Frantz RP, Grunig E, Jing ZC, Moiseeva O et al (2019) Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 53(1):1801889. https:\/\/doi.org\/10.1183\/13993003.01889-2018","journal-title":"Eur Respir J"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00673-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00673-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00673-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T07:06:29Z","timestamp":1702883189000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00673-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00673-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was reviewed and determined exempt by RTI International\u2019s institutional review board. Interview participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"In accordance with the informed-consent agreement, this publication includes no information that could personally identify participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SD is an employee of Janssen Pharmaceuticals, Inc. At the time of this research, JF was an employee of Janssen. AB is an employee of Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. At the time of this research, ME was an employee of Actelion. TE, LN, and SF are employees of RTI Health Solutions, which received funding from Janssen for conducting this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}